ImmunityBio, Inc. (IBRX) Stock Analysis — Probabli.AI
AI-powered analysis for IBRX (ImmunityBio, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. AI consensus: Bullish.
Last price: $6.96 · Market cap: $7.2B · AI consensus: Bullish
ImmunityBio, Inc. showcases outstanding revenue growth, robust development pipelines, and favorable buy-side consensus forecasts. Challenges such as regulatory scrutiny and patent disputes must be monitored closely but do not heavily detract from its long-term bullish outlook. Investors should expect significant price appreciation potential with moderate risk.
Probabilistic 1-Year Outlook
- Bull 4800% · Neutral 3500% · Bear 1700%
- ImmunityBio, Inc. demonstrates strong potential, given its rapid revenue growth estimate, recent positive trial data, and. analyst consensus with a strong buy rating. However, regulatory challenges and recent market…
5-Year Outlook
- Bull 6000% · Neutral 2500% · Bear 1500%
SWOT Highlights
- Strength: Strong revenue growth trajectory.
- Strength: Encouraging trial results for novel therapies.
- Risk: Negative recent price performance and volatility.
- Risk: Regulatory challenges including SEC investigation.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
7 Wall Street analysts rate IBRX a STRONG BUY with a mean price target of $12.57.
Analysis generated Apr 30, 2026 · Model: gpt-4o. Run a fresh analysis on probabli.xyz/stock/IBRX.
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.